Cayman Metamizole-d3 (sodium salt)

Metamizole-d₃ is intended for use as an internal standard for the quantification of metamizole (Item No. ) by GC- or LC-MS. Metamizole is a nonopioid prodrug that is rapidly hydrolyzed to the analgesic and antipyretic metabolites 4-methylaminoantipyrine (MAA) and 4-aminoantipyrine (AA). It inhibits COX-1 and COX-2 activity (IC₅₀ = ~150 µg/mL for both in cell-free assays), as well as reduces increases in intracellular calcium levels induced by the TRPA1 agonist AITC in isolated rat and mouse dorsal root ganglia and IMR-90 human fibroblasts (IC₅₀s = 30-91 µM in patch-clamp assays).^, Metamizole (6, 12, and 25 µg/mL) inhibits ADP- and epinephrine-induced platelet aggregation in human platelet-rich plasma (hPRP). It prevents fever induced by LPS, TNF-α, and IL-6, but not arachidonic acid (Item Nos. | 90010.1 | ) or prostaglandin E₂ (PGE₂; Item No. ), in rats when administered at a dose of 120 mg/kg. Metamizole (250 and 500 mg/kg) increases the paw withdrawal threshold in the paw pressure test, indicating analgesic activity, in rat models of carrageenan-induced acute pain and postoperative incision pain.

WARNING This product is not for human or veterinary use.